COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says
Flu Now Posing New Challenge
CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.
You may also be interested in...
The latest China biopharma trends, including Chinese biotech firms going overseas, post-COVID vaccine developments, new overseas data transfer standard contracts and developments at the Center for Drug Evaluation, are discussed in this Chinese-language podcast with Brian Yang in Beijing and Dexter Yan in Shanghai.
In this week's podcast version of Five Must-Know Things: ripples from SVB’s failure; Karuna’s schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China’s COVID vaccine lessons.
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.